# Predictive Biomarkers in Patients With Advanced Hepatocellular Carcinoma Treated With Systemic Therapy

> **NCT05197504** · — · COMPLETED · sponsor: **CHA University** · enrollment: 166 (actual)

## Conditions studied

- Hepatocellular Carcinoma

## Interventions

- **DRUG:** atezolizumab plus bevacizumab

## Key facts

- **NCT ID:** NCT05197504
- **Lead sponsor:** CHA University
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2021-12-20
- **Primary completion:** 2022-12-31
- **Final completion:** 2023-12-31
- **Target enrollment:** 166 (ACTUAL)
- **Last updated:** 2025-09-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05197504

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05197504, "Predictive Biomarkers in Patients With Advanced Hepatocellular Carcinoma Treated With Systemic Therapy". Retrieved via AI Analytics 2026-07-08 from https://api.ai-analytics.org/clinical/NCT05197504. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*